Genome Therapeutics Announces Date for Release of First Quarter Financial Results.Business Editors WALTHAM, Mass.--(BUSINESS WIRE)--May 1, 2003 Conference call to be held with members of senior management Genome Therapeutics (Nasdaq: GENE) will release financial results for the first quarter on Tuesday, May 13, 2003 prior to the opening of the U.S. financial markets. A conference call will be held at 9:00 AM ET with Steven Rauscher, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , and other members of senior management. Domestic participants can access the call by dialing 1-888-634-4009. International participants are asked to dial 1-706-634-2285. A replay will be available two hours after the conclusion of the call until May 20, 2003. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 259877. The call, and a replay of the webcast, will be available on the Company's website at www.genomecorp.com. About Genome Therapeutics Genome Therapeutics is a biopharmaceutical company focused on the discovery and development of pharmaceutical and diagnostics products. The Company's lead product candidate, Ramoplanin, is currently under Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA investigation for the prevention of bloodstream infections caused by vancomycin-resistant enterococci enterococci bacteria in the genus Enterococcus. (VRE VRE vancomycin-resistant enterococcus. VRE Vancomycin-resistent enterococcus, see there ), and under Phase II investigation for the treatment of Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. difficile-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator ). Genome Therapeutics' biopharmaceutical business includes a robust internal drug discovery program in the area of anti-infectives, and seven major product discovery alliances with several pharmaceutical companies including Amgen, AstraZeneca, bioMerieux, Schering-Plough and Wyeth. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion